Table 1 The in-vitro activities of 14 novel antimicrobial agents against 208 S. pneumoniae strains

PEN (Parenteral (nonmeningits))

≥ 8

42

9

13

23

40

47

28

2

4

1

4

202 (97.1)

6 (2.9)

PEN (Parenteral (meningitis))

≥ 0.12

42 (20.2)

166 (79.8)

PEN (Oral penicillin V)

≥ 2

127 (61.1)

81 (38.9)

CRO

≥ 4

49

19

37

50

20

19

9

2

3

0.25

2

194 (93.3)

14 (6.7)

ETP

≥ 4

185

14

3

4

1

1

0.25

0.25

206 (99.0)

2 (1.0)

CLI

≥ 1

8

2

1

3

194

2

2

11 (5.3)

197 (94.7)

ERY

≥ 1

2

5

201

4

4

0 (0.0)

208 (100.0)

DAP

≥ 2

124

1

39

27

8

6

1

2

0.064

0.5

199 (95.7)

9 (4.3)

TCY

≥ 4

11

1

4

8

18

166

16

16

16 (7.7)

192 (92.3)

TGC

≥ 0.125

191

15

1

1

0.064

0.125

191 (91.8)

17 (8.2)

ERV

≥ 0.125

105

99

3

1

< 0.064

0.064

204 (98.1)

4 (1.9)

OMC

≥ 0.5

27

109

59

12

1

0.064

0.125

207 (99.5)

1 (0.5)

LNZ

≥ 2

5

42

144

13

2

2

0.5

0.5

204 (98.1)

4 (1.9)

CZD

≥ 2

5

36

149

14

1

3

0.5

0.5

204 (98.1)

4 (1.9)

LVX

≥ 8

2

78

104

8

3

4

5

4

1

2

195 (93.7)

13 (6.3)

NAN

≥ 1

19

152

20

2

8

4

3

0.125

0.25

193 (92.8)

15 (7.2)